Rivabazumab pegol

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameRivabazumab pegol

Drug Alias NameAnti-PcrV mAb fragment抗PcrV单抗片段抗狂犬病疫苗抗体片段KB-001AKB-001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionType III secretion system protein inhibitors

TargetsType III secretion system protein

Therapy Area/IndicationsCystic FibrosisPneumonia, Ventilator-AssociatedPseudomonas Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNew ZealandAustralia +[5]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKalobios

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHumanigen Inc

Active IndicationsN/A

Inactive IndicationsCystic FibrosisPneumonia, Ventilator-AssociatedPseudomonas Infections

Other Information

ATC CodeN/A